American Headache Society 65th Annual Scientific Meeting (AHS 2023)

16 June 2023 - 18 June 2023

Fewer migraine days with dual therapy

Elvira Manzano, 20230717000000

Combination therapy with an anti-CGRP* monoclonal antibody (mAB) and onabotulinumtoxinA may be more effective than either therapy in patients with chronic migraine, according to a new study.

Fremanezumab eases migraine and depressive symptoms

Elvira Manzano, 20230713000000

Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.